UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.00001 par value (Title of Class of Securities)

> 23284F 10 5 (CUSIP Number)

December 31, 2017 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

- Rule 13d-1(c)
- □ Rule 13d-1(d)
- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 23284F 10 5

1	NAMES OF REPORTING PERSONS				
		ve Advisors LLC			
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) 🗆	(b) 🗆			
3	SEC USE				
5	3EC 03E	J UNE1			
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delawa	re			
		5 SOLE VOTING POWER			
-	IBER OF	0			
-	IARES FICIALLY	6 SHARED VOTING POWER			
	NED BY	2,400,201			
	ACH	2,490,381 7 SOLE DISPOSITIVE POWER			
	ORTING	7 SOLE DISPOSITIVE POWER			
	RSON VITH:	0			
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		8 SHARED DISPOSITIVE POWER			
		2,490,381			
9	AGGREO	GATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
2,490,381					
10	CHECK	BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) $\Box$			
11	DEDCEN	T OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
11	PERCEN	I OF CLASS REPRESENTED DT AMOUNT IN KOW 9			
	6.5%				
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)		REPORTING PERSON (SEE INSTRUCTIONS)			
	IA				

## CUSIP No. 23284F 10 5

CUSIPI	No. 23284F	10.5				
1 NAMES OF REPORTING PERSONS			EPORTING PERSONS			
	Joseph E	Edelı	nan			
2	CHECK T	THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
		. ,				
3	SEC USE ONLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION					
	United S	tate	s of America			
		5	SOLE VOTING POWER			
NUN	/IBER OF		0			
SI	HARES EFICIALLY	6	SHARED VOTING POWER			
H	EACH		2,490,381			
	ORTING ERSON	7	SOLE DISPOSITIVE POWER			
V	VITH:		0			
		8	SHARED DISPOSITIVE POWER			
	100000	A.1515	2,490,381			
9	AGGREG	AIE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
10	2,490,38		IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 🗆			
10						
11	PERCEN	ΓOF	CLASS REPRESENTED BY AMOUNT IN ROW 9			
	6.5%					
12	TYPE OF	REP	ORTING PERSON (SEE INSTRUCTIONS)			
	IN					

CUSIP No.	23284F	10 5
-----------	--------	------

	0.222041 10.5				
1	NAMES OF REPORTING PERSONS				
	Perceptive Life Sciences Master Fund, Ltd.				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (b) □				
-					
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Cayman Islands				
	5 SOLE VOTING POWER				
NUM	BER OF 6 SHARED VOTING POWER				
-	ARES				
	FICIALLY 2,490,381				
	ACH 7 SOLE DISPOSITIVE POWER				
	RSON				
	TTH: 0				
	8 SHARED DISPOSITIVE POWER				
	2,490,381				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
5					
	2,490,381				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	6 50/				
12	6.5%				
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	CO				

Item 1(a).	Name of Issuer:				
	CytomX Therapeutics, Inc. (the "Issuer")				
Item 1(b).	Address of Issuer's Principal Executive Offices:				
	151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080				
Item 2(a).	Names of Persons Filing:				
The na	names of the persons filing this report (collectively, the "Reporting Persons") are:				
	Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")				
Item 2(b).	Address of Principal Business Office or, if None, Residence:				
The add	ddress of the principal business office of each of the Reporting Persons is:				
	51 Astor Place, 10th Floor New York, NY 10003				
Item 2(c).	<u>Citizenship</u> :				
	Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation				
Item 2(d).	Title of Class of Securities:				
	Common Stock, \$0.00001 par value ("Common Stock")				
Item 2(e).	CUSIP Number:				
	23284F 10 5				
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	Not applicable.				
Item 4.	<u>Ownership</u> .				
	The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 38,408,626 outstanding shares of Common Stock, as reported in the Issuer's Form 10-Q filed on November 7, 2017.				

The Master Fund directly holds 2,490,381 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

#### Item 5. <u>Ownership of Five Percent or Less of a Class</u>.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\Box$ .

#### Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>.

Not applicable.

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

- Item 8.
   Identification and Classification of Members of the Group.

   Not applicable.
   Not applicable.
- Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

#### Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

#### SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2018

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name:Joseph EdelmanTitle:Managing Member